Effect of probiotics on Campylobacter colonisation within the broiler gut

A key component of the FSA work is to reduce the burden of foodborne disease in the UK. Campylobacter is the leading bacterial cause of foodborne disease in the UK, with chicken meat being the most common food source of exposure to this pathogen. Campylobacter is widespread in chicken farms, with 60% of UK broilers flocks carrying the pathogen at the point they are slaughtered. Interventions further down the food chain do not reliably eliminate this pathogen. Therefore, reducing Campylobacter colonisation on broiler flocks and contamination on chicken meat is a priority area for the FSA as this will contribute towards reducing human exposure and subsequent reported cases of foodborne disease.
A clear evidence gap remains on whether probiotics can consistently affect Campylobacter levels in broilers, across commercial UK farms under routine production conditions, and what magnitude of log reduction is realistically achievable.
To address this evidence gap, the FSA are seeking research proposals for an innovative field-trial based study carried out in real-life intensive broiler houses to assess the effectiveness of a range of probiotics on reducing or delaying Campylobacter colonisation in the gut of broiler flocks. The research should be designed to answer the following questions:
• “To what extent can commercially available probiotic formulations reduce or delay Campylobacter colonisation in broiler flocks under commercial intensive housed farming conditions, and does this translate into reduced Campylobacter contamination of carcasses at processing?”
• “What is the effect of these formulations on welfare and production performance indicators such as mortality, growth rate, feed conversion efficiency and flock health outcomes?”
We envisage that the proposed study design will consist of several discrete phases.
Given the complexity of controlling Campylobacter in broiler flocks, we would like the inclusion of break clauses at the end of key deliverables to allow sufficient time for the FSA, together with the researcher team, to review the phase findings and determine whether there is sufficient evidence and justification to proceed to the next stage of the project. If not, then the FSA reserves the right to terminate the project.

Communication: Tenders for FSA funded projects must be submitted through the health-family single e-Commercial System (Atamis), using the following link: https://health-family.force.com/s/Welcome
Enquiry deadline: 2026-11-11T12:00:00Z
Submission address and any special instructions: Tenders for FSA funded projects must be submitted through the health-family single e-Commercial System (Atamis), using the following link: https://health-family.force.com/s/Welcome
Tenders may be submitted electronically: allowed
Award decision date (estimated): 2026-12-14T23:59:59Z

Lot: 1
Lot value (estimated)
500.000,00 GBP excluding VAT
600.000,00 GBP including VAT
This contract is subject to renewal: Yes
Description of renewals: optional 12 month extension option.
Information about options. Options: Yes

Award criteria:

Name	Type	Weighting
Technical	quality	80%
Commercial	cost	20%

Languages in which tenders or requests to participate may be submitted: En